Immune check point antibodies, such as anti-PD1, anti-PD-L1, anti-CTLA4 have led to breakthroughs for the treatment of many tumor types; However, tumor types such as HCC, pancreatic and colon cancers have had relatively low response rates to these antibodies. This evidence concerns the gene CTLA4 and colonic neoplasm.